Directly Observed Hepatitis C Treatment in Methadone Clinics

美沙酮诊所直接观察的丙型肝炎治疗

• 批准号: 7385502
• 负责人: Alain Harris Litwin
• 金额: $ 17.89万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7385502
• 关键词: Abstinence; Adherence; Adverse effects; Agonist; Alcohol consumption; Area; Award; Behavior Therapy; Belief; Caring; Characteristics; Clinical Research; Clinical Trials; Communicable Diseases; Consensus; Count; Daily; Data; Development; Directly Observed Therapy; Disease; Doctor of Medicine; Dose; Drug usage; Drug user; End Point; Enrollment; Goals; Guidelines; HIV; Hepatitis C; Hepatitis C virus; Highly Active Antiretroviral Therapy; Home environment; Housing; Individual; Injecting drug user; Injection of therapeutic agent; Interferons; Intervention; Knowledge; Master of Public Health; Measures; Mental Depression; Mentors; Mentorship; Methadone; Modeling; Motivation; NIH Consensus Development Conferences; Numbers; Opiates; Opioid; Outcome; Patient Self-Report; Patients; Perception; Pharmaceutical Preparations; Provider; Randomized; Randomized Controlled Clinical Trials; Randomized Controlled Trials; Research; Research Design; Ribavirin; Risk; Self Administration; Self Efficacy; Self-Administered; Site; Social support; Standards of Weights and Measures; Statistical Methods; Substance abuse problem; Testing; Time; Training; Treatment Protocols; Treatment outcome; United States; United States National Institutes of Health; Upper arm; Vertebral column; Viral; Week; community based participatory research; cost effectiveness; day; design; improved; interferon therapy; methadone clinic/center; peginterferon alfa-2a; pill; programs; response; skills; subcutaneous; success; treatment program; tuberculosis treatment

DESCRIPTION (provided by applicant): Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the United States infected with hepatitis C virus (HCV), and the majority of drug users in opioid agonist treatment programs have HCV. Even though there are effective HCV treatments, alarmingly few drug users and opioid agonist maintained patients have initiated HCV treatment. Because HCV has a discrete course of treatment lasting only 24 to 48 weeks and its backbone is once-weekly subcutaneous pegylated interferon injections, it may be ideally suited for directly observed treatment (DOT) management. To test this, we have designed a small randomized controlled trial of modified DOT (mDOT) for HCV treatment (both pegylated interferon and ribavirin) in drug users enrolled in opioid agonist treatment. The goal of this mentored award is to enhance the clinical research skills of Alain Litwin, M.D., M.P.H., M.S., through research on integrating HCV treatment with substance abuse treatment. Dr. Litwin's training plan involves formal mentorship in the following areas: implementing comprehensive DOT programs in opiate agonist programs, measuring and analyzing adherence in drug users, designing behavioral interventions for drug users, clinical trial study design, advanced statistical methods, and community-based participatory research. The specific aims of this proposal are: (1) To determine in randomized trial whether modified directly observed HCV treatment (pegylated interferon alfa-2a plus ribavirin) provided on-site at a methadone program is more efficacious than self-administered HCV treatment for enhancing adherence; (2) To determine the impact of providing on-site HCV treatment on virologic outcomes, and to determine the association between HCV treatment adherence and virologic outcomes. As a sub-aim, we will also determine whether mDOT is more efficacious than self-administered HCV treatment for achieving HCV treatment outcomes; and (3) To identify individual-level factors (e.g. active drug and alcohol use, active psychiatric illness, housing status, social support, beliefs and knowledge about HCV medications, motivation to adhere, self-efficacy, and medication side effects) influencing HCV treatment adherence and HCV treatment outcomes. Findings from this project will be used to inform the development of a large randomized trial of the efficacy and cost-effectiveness of modified directly observed HCV care versus regular on-site care.

描述（由申请人提供）：注射吸毒者（IDUs）占美国约500万丙型肝炎病毒（HCV）感染者的60%，阿片类激动剂治疗项目中的大多数吸毒者患有HCV。尽管有有效的HCV治疗，但令人担忧的是，很少有吸毒者和阿片类激动剂维持患者开始HCV治疗。由于HCV具有仅持续24至48周的离散疗程，并且其骨干是每周一次皮下注射聚乙二醇干扰素，因此它可能非常适合直接观察治疗（DOT）管理。为了验证这一点，我们设计了一个小型的随机对照试验，在阿片类激动剂治疗的吸毒者中使用改良DOT（mDOT）治疗HCV（聚乙二醇干扰素和利巴韦林）。这个指导奖的目标是提高阿兰利特温，医学博士，最大功率，医学硕士，通过研究将HCV治疗与药物滥用治疗相结合。Litwin博士的培训计划涉及以下领域的正式指导：在阿片类激动剂项目中实施全面的DOT项目，测量和分析吸毒者的依从性，为吸毒者设计行为干预措施，临床试验研究设计，先进的统计方法和基于社区的参与性研究。本建议的具体目的是：（1）在随机试验中确定是否修改直接观察HCV治疗（聚乙二醇干扰素α-2a加利巴韦林）在美沙酮项目现场提供比自我管理的HCV治疗更有效，以提高依从性;（2）确定提供现场HCV治疗对病毒学结果的影响，并确定HCV治疗依从性和病毒学结果之间的关系。作为一个子目标，我们还将确定mDOT是否比自我管理的HCV治疗更有效，以实现HCV治疗结果;（3）识别个体层面的影响因素（例如，活动性药物和酒精使用，活动性精神疾病，住房状况，社会支持，对HCV药物的信念和知识，坚持的动机，自我效能，和药物副作用）影响HCV治疗依从性和HCV治疗结果。该项目的研究结果将用于制定一项大型随机试验，研究改良直接观察HCV护理与常规现场护理的疗效和成本效益。